Goserelin
"Goserelin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.
Descriptor ID |
D017273
|
MeSH Number(s) |
D06.472.699.327.740.320.340 D12.644.400.400.740.320.340 D12.644.456.460.315 D12.644.548.365.740.320.340 D12.776.641.650.405.740.320.340
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Goserelin".
Below are MeSH descriptors whose meaning is more specific than "Goserelin".
This graph shows the total number of publications written about "Goserelin" by people in this website by year, and whether "Goserelin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 1 | 1 | 2005 | 0 | 1 | 1 | 2007 | 0 | 1 | 1 | 2008 | 0 | 1 | 1 | 2015 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Goserelin" by people in Profiles.
-
Wolfe T, Chatterjee D, Lee J, Grant JD, Bhattarai S, Tailor R, Goodrich G, Nicolucci P, Krishnan S. Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo. Nanomedicine. 2015 Jul; 11(5):1277-83.
-
D'Amico AV, Chen MH, Renshaw AA, Loffredo B, Kantoff PW. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol. 2008 Jun 20; 26(18):2979-83.
-
D'Amico AV, Renshaw AA, Loffredo B, Chen MH. Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy. Cancer. 2007 Oct 15; 110(8):1723-8.
-
Johnke RM, Edwards JM, Kovacs CJ, Evans MJ, Daly BM, Karlsson UL, Lee TK, Allison RR, Arastu HH, Cariveau MJ, O'Brien KF. Response of T lymphocyte populations in prostate cancer patients undergoing radiotherapy: influence of neoajuvant total androgen suppression. Anticancer Res. 2005 Jul-Aug; 25(4):3159-66.
-
D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004 Aug 18; 292(7):821-7.
|
People ![Expand Description](http://scholarprofile.org/Framework/Images/info.png) People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|